All patients
Age < 65y (younger) Age > 65y Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 EGFR mutant Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 (TC2/3 or IC2/3 : ≥5% of TC or IC) PDL1 (TC3 or IC3 : ≥50% of TC or ≥10% of IC ) smoker (current or former) smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), atezolizumab alone vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.83 [0.65; 1.06]
IMpower-110 (TC2/3 or IC2/3), 2020 0.72 [0.52; 0.99]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.40; 0.88]
OAK (all population), 2016 0.80 [0.70; 0.92]
OAK (PDL1 TC 1/2/3), 2016 0.77 [0.64; 0.92]
POPLAR, 2016 0.73 [0.53; 1.00]
0.77 [0.71 ; 0.84 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 6 0% 3,283 moderate serious deaths (OS) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 0.76 [0.53; 1.08]
0.76 [0.53 ; 1.08 ] IMpower-110 (TC3 or IC3), 2020 1 0% 205 NA not evaluable PFS (extension)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.72 [0.60; 0.86]
IMpower-110 (TC2/3 or IC2/3), 2020 0.64 [0.50; 0.82]
IMpower-110 (TC3 or IC3), 2020 0.59 [0.43; 0.81]
0.67 [0.59 ; 0.77 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020 3 0% 1,087 moderate not evaluable progression or deaths (PFS)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.77 [0.63; 0.94]
IMpower-110 (TC2/3 or IC2/3), 2020 0.67 [0.52; 0.87]
IMpower-110 (TC3 or IC3), 2020 0.63 [0.45; 0.88]
OAK (all population), 2016 0.96 [0.85; 1.08]
OAK (PDL1 TC 1/2/3), 2016 0.87 [0.74; 1.03]
POPLAR, 2016 0.94 [0.72; 1.23]
0.82 [0.72 ; 0.94 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 6 57% 3,283 moderate serious DORdetailed results OAK (PDL1 TC 1/2/3), 2016 9.61 [3.07; 30.08]
9.61 [3.07 ; 30.08 ] OAK (PDL1 TC 1/2/3), 2016 1 0% 107 NA not evaluable objective responses (ORR)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.89 [0.62; 1.27]
IMpower-110 (TC2/3 or IC2/3), 2020 0.94 [0.59; 1.50]
IMpower-110 (TC3 or IC3), 2020 1.55 [0.86; 2.79]
OAK (all population), 2016 1.19 [0.85; 1.67]
OAK (PDL1 TC 1/2/3), 2016 1.41 [0.93; 2.14]
POPLAR, 2016 0.99 [0.52; 1.91]
1.12 [0.94 ; 1.33 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, IMpower-110 (TC2/3 or IC2/3), 2020, IMpower-110 (TC3 or IC3), 2020, OAK (all population), 2016, OAK (PDL1 TC 1/2/3), 2016, POPLAR, 2016 6 0% 3,283 moderate not evaluable objective responses (ORR) (extension)detailed results IMpower-110 (TC3 or IC3), 2020 1.68 [0.94; 3.01]
1.68 [0.94 ; 3.01 ] IMpower-110 (TC3 or IC3), 2020 1 0% 205 NA not evaluable AE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.52 [0.27; 1.01]
OAK (all population), 2016 0.66 [0.39; 1.13]
POPLAR, 2016 0.87 [0.26; 2.93]
0.62 [0.42 ; 0.93 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016, POPLAR, 2016 3 0% 2,013 moderate not evaluable AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.39 [0.27; 0.55]
OAK (all population), 2016 0.51 [0.41; 0.65]
POPLAR, 2016 0.60 [0.38; 0.97]
0.49 [0.39 ; 0.60 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016, POPLAR, 2016 3 22% 2,013 moderate not evaluable AE leading to death (grade 5)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.39; 2.15]
OAK (all population), 2016 0.67 [0.30; 1.53]
POPLAR, 2016 1.15 [0.34; 3.85]
0.84 [0.49 ; 1.43 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016, POPLAR, 2016 3 0% 2,013 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.34 [0.19; 0.61]
OAK (all population), 2016 0.58 [0.45; 0.75]
POPLAR, 2016 0.29 [0.14; 0.61]
0.43 [0.27 ; 0.68 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016, POPLAR, 2016 3 60% 2,013 moderate not evaluable SAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.99 [0.68; 1.44]
POPLAR, 2016 1.05 [0.64; 1.73]
1.01 [0.75 ; 1.36 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, POPLAR, 2016 2 0% 826 moderate not evaluable SAE (grade 3-4)detailed results OAK (all population), 2016 1.03 [0.80; 1.31]
1.03 [0.80 ; 1.31 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable STRAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.50 [0.29; 0.85]
0.50 [0.29 ; 0.85 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable TRAE (any grade)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.27 [0.18; 0.40]
OAK (all population), 2016 0.29 [0.22; 0.39]
POPLAR, 2016 0.27 [0.15; 0.51]
0.28 [0.23 ; 0.35 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016, POPLAR, 2016 3 0% 2,013 moderate not evaluable TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.19 [0.12; 0.29]
OAK (all population), 2016 0.23 [0.18; 0.31]
POPLAR, 2016 0.20 [0.11; 0.38]
0.22 [0.17 ; 0.27 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016, POPLAR, 2016 3 0% 2,013 moderate not evaluable TRAE leading to death (grade 5)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
OAK (all population), 2016 0.47 [0.02; 14.16]
POPLAR, 2016 0.31 [0.03; 3.04]
0.38 [0.07 ; 1.97 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016, POPLAR, 2016 3 0% 2,013 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results POPLAR, 2016 0.07 [0.02; 0.29]
0.07 [0.02 ; 0.29 ] POPLAR, 2016 1 0% 277 NA not evaluable Colitis TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
3.70 [0.17 ; 82.36 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 11.47 [1.48; 88.87]
11.47 [1.48 ; 88.87 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
0.92 [0.02 ; 46.51 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
0.92 [0.02 ; 46.51 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.92 [0.02; 46.51]
0.92 [0.02 ; 46.51 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
3.70 [0.17 ; 82.36 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Rash TRAE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
1.38 [0.23 ; 8.34 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Alopecia AE (grade 3-4)detailed results OAK (all population), 2016 0.47 [0.02; 14.16]
0.47 [0.02 ; 14.16 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Anaemia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.08 [0.03; 0.20]
OAK (all population), 2016 0.39 [0.21; 0.73]
0.18 [0.04 ; 0.86 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 87% 1,736 moderate not evaluable Arthralgia AE (grade 3-4)detailed results OAK (all population), 2016 2.86 [0.30; 27.54]
2.86 [0.30 ; 27.54 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Asthenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.36 [0.07; 1.89]
OAK (all population), 2016 0.58 [0.24; 1.41]
0.52 [0.24 ; 1.14 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 0% 1,736 moderate not evaluable Back pain AE (grade 3-4)detailed results OAK (all population), 2016 1.67 [0.49; 5.73]
1.67 [0.49 ; 5.73 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Constipation AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.38 [0.23; 8.34]
OAK (all population), 2016 1.90 [0.17; 21.02]
1.55 [0.37 ; 6.54 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 0% 1,736 moderate not evaluable Cough AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1.84 [0.06; 55.14]
OAK (all population), 2016 1.90 [0.17; 21.02]
1.88 [0.26 ; 13.39 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 0% 1,736 moderate not evaluable Decreased appetite AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
OAK (all population), 2016 0.21 [0.04; 0.97]
0.63 [0.04 ; 9.82 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 62% 1,736 moderate not evaluable Diarrhoea AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.01; 5.09]
OAK (all population), 2016 0.34 [0.11; 1.08]
0.32 [0.11 ; 0.95 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 0% 1,736 moderate not evaluable Dysgeusia AE (grade 3-4)detailed results OAK (all population), 2016 0.95 [0.02; 47.91]
0.95 [0.02 ; 47.91 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Dyspnoea AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 3.70 [0.17; 82.36]
OAK (all population), 2016 1.02 [0.49; 2.13]
1.09 [0.53 ; 2.23 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 0% 1,736 moderate not evaluable Fatigue AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.30 [0.06; 1.51]
OAK (all population), 2016 0.69 [0.37; 1.31]
0.62 [0.34 ; 1.12 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 0% 1,736 moderate not evaluable Febrile neutropenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.05 [0.00; 0.86]
OAK (all population), 2016 0.01 [0.00; 0.10]
0.02 [0.00 ; 0.11 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 0% 1,736 moderate not evaluable Hypertension AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.61 [0.10; 3.68]
0.61 [0.10 ; 3.68 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Increase AST AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17]
4.66 [0.54 ; 40.17 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Increased ALT AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 4.66 [0.54; 40.17]
4.66 [0.54 ; 40.17 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Leucopenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.23 [0.03; 2.05]
0.23 [0.03 ; 2.05 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Myalgia AE (grade 3-4)detailed results OAK (all population), 2016 0.24 [0.03; 2.12]
0.24 [0.03 ; 2.12 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Nausea AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.18 [0.02; 1.56]
OAK (all population), 2016 1.90 [0.35; 10.44]
0.65 [0.06 ; 6.44 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 65% 1,736 moderate not evaluable Neutropenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.03 [0.01; 0.14]
OAK (all population), 2016 0.03 [0.01; 0.11]
0.03 [0.01 ; 0.08 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 0% 1,736 moderate not evaluable Pancytopenia (AE grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08]
0.46 [0.04 ; 5.08 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results OAK (all population), 2016 0.07 [0.00; 1.18]
0.07 [0.00 ; 1.18 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Peripheral oedema AE (grade 3-4)detailed results OAK (all population), 2016 0.32 [0.03; 3.04]
0.32 [0.03 ; 3.04 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Pneumonia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.71 [0.26; 1.93]
0.71 [0.26 ; 1.93 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Pyrexia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.02; 13.73]
OAK (all population), 2016 0.95 [0.06; 15.21]
0.71 [0.08 ; 6.09 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 0% 1,736 moderate not evaluable Sepsis AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08]
0.46 [0.04 ; 5.08 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Stomatitis AE (grade 3-4)detailed results OAK (all population), 2016 0.08 [0.01; 0.66]
0.08 [0.01 ; 0.66 ] OAK (all population), 2016 1 0% 1,187 NA not evaluable Thrombocytopenia AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.05 [0.01; 0.34]
0.05 [0.01 ; 0.34 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020 1 0% 549 NA not evaluable Vomiting AE (grade 3-4)detailed results IMpower-110 (TC1/2/3 or IC1/2/3), 2020 0.46 [0.04; 5.08]
OAK (all population), 2016 0.47 [0.09; 2.59]
0.47 [0.12 ; 1.88 ] IMpower-110 (TC1/2/3 or IC1/2/3), 2020, OAK (all population), 2016 2 0% 1,736 moderate not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-14 11:02 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 161,226,41,225,182,198,179,200,195,254,242,243,199,190,229,266,191,196,36,228,174,171,173,307,165,163,176,308,164,166,220,197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169,335,334
- treatments: 361
